Amcyte Pharma’s pipeline includes several cytokines and immunomodulators that enhance the activity of new cell therapy treatments by stimulating Treg proliferation and controlling side effects of the therapies for both leukemias and solid tumors.
Our pipeline also includes targets for several orphan diseases that provide affordable and improved therapeutic profiles against existing treatments.
- Technology: Low dose IL-2
- Indication: Graft vs Host Disease treatment
- Development: Phase I
- Commercial Partner: Amcyte
- Technology: Low dose IL-2
- Indication: Cell Therapy adjuvant
- Development: Preclinical
- Commercial Partner: Undisclosed Partner
- Technology: Low dose IL-2
- Indication: Cell Therapy adjuvant
- Development: Preclinical
- Commercial Partner: Confidential
- Technology: IL12-IL15 fusion
- Indication: Solid tumor
- Development: Development
- Commercial Partner: Amcyte
- Technology: IL35 Peptide
- Indication: Immune diseases
- Development: Development
- Commercial Partner: Amcyte
Program Development
IL-2
Interleukine-2 (IL2) is a key cytokine involved in the activation and proliferation of T lymphocytes, specifically as being an essential cytokine for the survival and activation of Tregs. IL-2 binds to three different subunits of the same receptor: IL2-Rα (high affinity), IL2-Rβ (medium affinity) and IL2-Rγ (low affinity). While Teffs only express IL2-Rβ and IL2-Rγ receptors, Tregs express the “high affinity” receptor IL2-Rα, therefore showing a preferential uptake of IL2.
Low-dose IL2 support the in-vivo specific proliferation of Tregs, providing a promising adjuvant effect to different modalities of Cell Therapy treatments.
Modified IL-12/IL-15
NK cells are effector lymphocytes that are under clinical investigation for the adoptive immunotherapy of hematologic malignancies, especially acute myeloid leukemia. Recent work in mice has identified innate memory-like properties of NK cells. Human NK cells also exhibit memory-like properties, and cytokine-induced memory-like (CIML) NK cells are generated via brief pre-activation with IL-12, IL-15, and IL-18. Our IL15 long-acting antagonist formulation allows for in-vivo re-stimulation of CIML NK cells yielding a more effective therapy.
